NCT06711471 2024-12-02
Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
Clinical Trials
1 trialsPhase 2 × Gastric Cancer Adenocarcinoma Metastatic × trifluridine tipiracil drug combination × Clear all